X4 Pharmaceuticals (NASDAQ:XFOR) Posts Quarterly Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) posted its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04, FiscalAI reports. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 118.77%. The business had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $3.20 million.

X4 Pharmaceuticals Price Performance

XFOR stock opened at $4.29 on Friday. The stock has a market capitalization of $390.05 million, a price-to-earnings ratio of -0.94 and a beta of 0.31. The company has a quick ratio of 9.98, a current ratio of 10.16 and a debt-to-equity ratio of 0.41. X4 Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $4.83. The stock’s fifty day simple moving average is $4.03 and its 200-day simple moving average is $3.82.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Bain Capital Life Sciences Investors LLC boosted its holdings in shares of X4 Pharmaceuticals by 227.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock valued at $31,870,000 after purchasing an additional 5,530,866 shares during the last quarter. Kalehua Capital Management LLC acquired a new stake in X4 Pharmaceuticals during the fourth quarter worth about $14,891,000. Braidwell LP purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter worth about $13,476,000. Nantahala Capital Management LLC acquired a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at about $7,621,000. Finally, Siren L.L.C. acquired a new stake in X4 Pharmaceuticals during the 4th quarter worth approximately $6,000,000. 72.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on XFOR shares. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Wall Street Zen raised X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Guggenheim initiated coverage on shares of X4 Pharmaceuticals in a research note on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, X4 Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $8.50.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.